Biotechnology

By Maggie Fox, health and science editor Maggie Fox, health and science Editor-Mountain Nov 22, 6: 19 h. HITTITES WASHINGTON (Reuters)-Christopher Goodrich, Portland, Oregon, can't wait for a needle in his eyes. Goodrich was expected to be one of the first patients were enrolled in clinical trial this only a sound States food and drug administration, only the second judgment approved anywhere in the world test globil human milk stem in the people. Advanced cell technology, a Massachusetts-based company biotechnologie did evil to bring globil human milk stem in the lab to the clinic, recrutement 12 patients start in Oregon, Massachusetts and eye condition called scarce Stargardt (k will be put to death. Goodrich, 55, retired last year of his work as Coordinator for services to the University of Portland State when Stargardt (k death completely inexplicable and suddenly take a turn for the worse. Like most patients Goodrich, saw the vision, it gets worse steadily from his earliest da...

LOS ANGELES (Reuters)-a pivotal trial of experimental cancer targeting antibody Seattle Genetics for sick and UN Crowfoot Hodgkin the study found that more than a third country realized all point reduction of cancer. The company also said he hopes to submit the drug, brentuximab vedotin, u. s. regulator in the first half of next year for the sick and night Crowfoot Hodgkin or the UN UN large cell anaplastic (ALCL) who suspended in response to other thérapies. The company was a précédemment soumission would in the first half of 2011. Was '' our goal should submit in the first season, there is a review accéléré economic and trade market in 2011, "Chief Executive of Clay Siegall Seattle genetics said in an interview by telephone. Judging by vedotin brentuximab compared with another drug, but rate reduction on all fronts for patients in the same way tends, Pasco Bachelor, he said. The company developed UN drug and medicine Takeda Co., Japan and European regulators to discuss ...

LOS ANGELES (Reuters)-Dugmaker Cephalon Inc. plans to have a guiding companies biotechnologie Australian Mesoblast Ltd as well as rights to develop stem cell for his old traitements dégénératives e conditions of cardiovascular and Central nerveux. News of the action of Mesoblast up 27 percent of the value of the Australian early Wednesday. On the compact, the Cephalon Mesoblast pay $ 130 million avance and another 220 million dollars to have a nearly 20 percent through the Australian company, said in a statement. Cephalon will not have rights around the world for specific products based on adult stem cell technology platform Mesoblast. Globil old stem, opposition to pack up more controversial embryonic cell stem red there is a limited ability to form new types of packed red blood cells and tissus. Companies said payment total advance regulation to Mesoblast could reach $ 1.7 million, accept that the deal results in the traitements commercial for conditions including congestive heart f...